BRPI0717335A2 - Anticorpos anti-htnfalfa cristalinos - Google Patents

Anticorpos anti-htnfalfa cristalinos

Info

Publication number: BRPI0717335A2
Authority: BR; Brazil
Prior art keywords: htnfalfa; crystaline; antibodies; crystals; antibody
Prior art date: 2006-10-27

Application number

BRPI0717335-0A2A

Other languages

English (en)

Inventor

David W Borhani

Wolfgang Fraunhofer

Hans-Juergen Krause

Anette Koenigsdorfer

Gerhard Winter

Stefan Gottschalk

Original Assignee

Abbott Biotech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-27

Filing date

2007-10-25

Publication date

2013-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39364990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0717335(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-10-25 Application filed by Abbott Biotech Ltd filed Critical Abbott Biotech Ltd

2013-12-10 Publication of BRPI0717335A2 publication Critical patent/BRPI0717335A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Virology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)

BRPI0717335-0A2A 2006-10-27 2007-10-25 Anticorpos anti-htnfalfa cristalinos BRPI0717335A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US85510406P	2006-10-27	2006-10-27
PCT/US2007/022622 WO2008057240A2 (en)	2006-10-27	2007-10-25	Crystalline anti-htnfalpha antibodies

Publications (1)

Publication Number	Publication Date
BRPI0717335A2 true BRPI0717335A2 (pt)	2013-12-10

Family

ID=39364990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717335-0A2A BRPI0717335A2 (pt)	2006-10-27	2007-10-25	Anticorpos anti-htnfalfa cristalinos

Country Status (21)

Country	Link
US (4)	US8034906B2 (pt)
EP (2)	EP2089428B1 (pt)
JP (2)	JP2010507670A (pt)
KR (2)	KR20090101893A (pt)
CN (2)	CN101616932A (pt)
AR (1)	AR063429A1 (pt)
AU (1)	AU2007318120B2 (pt)
BR (1)	BRPI0717335A2 (pt)
CA (1)	CA2667655A1 (pt)
CL (1)	CL2007003094A1 (pt)
ES (1)	ES2442258T3 (pt)
IL (1)	IL198223A (pt)
MX (1)	MX2009004351A (pt)
NZ (3)	NZ597676A (pt)
PE (2)	PE20081258A1 (pt)
RU (2)	RU2486296C2 (pt)
SG (1)	SG176427A1 (pt)
TW (2)	TWI417302B (pt)
UY (1)	UY30662A1 (pt)
WO (1)	WO2008057240A2 (pt)
ZA (1)	ZA201306383B (pt)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
CN103275221B (zh)	1996-02-09	2016-08-17	艾伯维生物技术有限公司	结合人TNFα的人抗体
CA2868614A1 (en)	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
NZ563452A (en) *	2002-07-19	2010-04-30	Abbott Biotech Ltd	Treatment of TNFalpha related disorders
US20090280065A1 (en) *	2006-04-10	2009-11-12	Willian Mary K	Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI556829B (zh)	2004-04-09	2016-11-11	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
WO2006041970A2 (en) *	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
EP2500037A3 (en)	2005-05-16	2012-10-24	Abbott Biotechnology Ltd	Use of TNF alpha inhibitor for treatment of erosive polyarthritis
BRPI0611901A2 (pt)	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
EP1948235B1 (en)	2005-11-01	2013-08-28	AbbVie Biotechnology Ltd	Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
CN101506236B (zh)	2005-11-30	2012-12-12	雅培制药有限公司	抗淀粉样β蛋白的单克隆抗体及其用途
DK1954718T3 (en)	2005-11-30	2014-12-15	Abbvie Inc	Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
EP2738178A1 (en)	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Antibody purification
US20080118496A1 (en) *	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) *	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
US20090317399A1 (en) *	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
WO2007120656A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (en)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Uses and compositions for treatment of psoriatic arthritis
WO2007120626A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) *	2006-06-08	2008-12-18	Hoffman Rebecca S	Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) *	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
WO2008005315A2 (en)	2006-06-30	2008-01-10	Abbott Biotechnology Ltd.	Automatic injection device
BRPI0717335A2 (pt)	2006-10-27	2013-12-10	Abbott Biotech Ltd	Anticorpos anti-htnfalfa cristalinos
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en)	2007-02-27	2010-12-09	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
MX2009010361A (es)	2007-03-29	2009-10-16	Abbott Lab	Anticuerpos il-12 anti-humanos cristalinos.
EP2137655B1 (en) *	2007-04-16	2012-07-11	Momenta Pharmaceuticals, Inc.	Defined glycoprotein products and related methods
US8092998B2 (en) *	2007-05-31	2012-01-10	Abbott Laboratories	Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2171451A4 (en)	2007-06-11	2011-12-07	Abbott Biotech Ltd	METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CA2693771A1 (en) *	2007-07-13	2009-01-22	Abbott Biotechnology Ltd.	Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
SG183709A1 (en)	2007-08-08	2012-09-27	Abbott Lab	Compositions and methods for crystallizing antibodies
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
EP2235059B1 (en)	2007-12-26	2015-02-18	Xencor, Inc.	Fc variants with altered binding to fcrn
MX2010007393A (es) *	2008-01-03	2010-11-09	Abbott Biotech Ltd	Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
JP6078217B2 (ja)	2008-01-15	2017-02-08	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	粉末化されたタンパク質組成物及びその作製方法
CN102065892A (zh) *	2008-01-30	2011-05-18	雅培制药有限公司	用于使抗体片段结晶的组合物和方法
MX2010011955A (es)	2008-04-29	2011-01-21	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102112494A (zh) *	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
NZ595687A (en)	2009-04-16	2013-11-29	Abbvie Biotherapeutics Inc	Anti-tnf-alpha antibodies and their uses
US8636704B2 (en) *	2009-04-29	2014-01-28	Abbvie Biotechnology Ltd	Automatic injection device
SG175188A1 (en) *	2009-05-04	2011-11-28	Abbott Biotech Ltd	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP3466438A1 (en)	2009-08-03	2019-04-10	Incube Labs, Llc	Swallowable capsule and method for stimulating incretin production within the intestinal tract
NZ627052A (en) *	2009-12-15	2015-12-24	Abbvie Biotechnology Ltd	Improved firing button for automatic injection device
US8759284B2 (en)	2009-12-24	2014-06-24	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20110223208A1 (en) *	2010-03-09	2011-09-15	Beth Hill	Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CN103096934A (zh) *	2010-03-09	2013-05-08	詹森生物科技公司	非水性高浓度低粘度混悬剂
US9072668B2 (en)	2010-03-09	2015-07-07	Janssen Biotech, Inc.	Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2011127322A1 (en)	2010-04-07	2011-10-13	Momenta Pharmaceuticals, Inc.	High mannose glycans
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
CN103080130B (zh)	2010-05-27	2016-08-17	默沙东公司	制备具有改进特性的抗体的方法
PL2575884T3 (pl)	2010-06-03	2018-12-31	Abbvie Biotechnology Ltd	Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)
MX341579B (es)	2010-08-03	2016-08-25	Abbvie Inc *	Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP6147665B2 (ja)	2010-08-14	2017-06-14	アッヴィ・インコーポレイテッド	アミロイドベータ結合タンパク質
BR112013004581A2 (pt)	2010-08-26	2017-06-27	Abbvie Inc	imunoglobulinas de domínio variável dual e seus usos
AR083495A1 (es)	2010-10-22	2013-02-27	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles
US8821865B2 (en)	2010-11-11	2014-09-02	Abbvie Biotechnology Ltd.	High concentration anti-TNFα antibody liquid formulations
US9861683B2 (en)	2010-12-23	2018-01-09	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en)	2010-12-23	2016-02-16	Rani Therapeutics, Llc	Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en)	2010-12-23	2017-04-25	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en)	2010-12-23	2014-05-27	Rani Therapeutics, Llc	Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en)	2010-12-23	2015-03-17	Rani Therapeutics, Llc	Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en)	2010-12-23	2020-05-05	Rani Therapeutics, Llc	Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en)	2010-12-23	2016-08-02	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en)	2010-12-23	2016-03-15	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en)	2010-12-23	2014-08-19	Rani Therapeutics, Llc	Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) *	2010-12-23	2016-08-16	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en)	2010-12-23	2015-03-03	Rani Therapeutics, Llc	Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en)	2010-12-23	2015-10-06	Rani Therapeutics, Llc	Device, system and methods for the oral delivery of therapeutic compounds
US8846040B2 (en)	2010-12-23	2014-09-30	Rani Therapeutics, Llc	Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8764733B2 (en)	2010-12-23	2014-07-01	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en)	2010-12-23	2016-03-15	Rani Therapeutics, Llc	GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en)	2010-12-23	2016-08-02	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en)	2010-12-23	2014-08-19	Rani Therapeutics, Llc	Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
BR112013018905B1 (pt)	2011-01-24	2021-07-13	Abbvie Biotechnology Ltd	Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
US9170249B2 (en)	2011-03-12	2015-10-27	Momenta Pharmaceuticals, Inc.	N-acetylhexosamine-containing N-glycans in glycoprotein products
EP2702077A2 (en)	2011-04-27	2014-03-05	AbbVie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201112429D0 (en) *	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
UY34558A (es)	2011-12-30	2013-07-31	Abbvie Inc	Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9181572B2 (en) *	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
US20150204884A1 (en) *	2012-06-01	2015-07-23	Momenta Pharmaceuticals, Inc.	Methods of evaluating and making biologics
US9695244B2 (en)	2012-06-01	2017-07-04	Momenta Pharmaceuticals, Inc.	Methods related to denosumab
WO2013181585A2 (en) *	2012-06-01	2013-12-05	Momenta Pharmaceuticals, Inc.	Methods related to adalimumab
US9803010B2 (en)	2012-06-27	2017-10-31	Merck Sharp & Dohme Corp.	Crystalline anti-human IL-23p19 antibodies
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
AU2013309506A1 (en)	2012-09-02	2015-03-12	Abbvie Inc.	Methods to control protein heterogeneity
MY194330A (en)	2012-11-01	2022-11-28	Abbvie Inc	Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
WO2014143205A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
EP2970375A1 (en)	2013-03-14	2016-01-20	AbbVie Inc.	Low acidic species compositions and methods for producing the same using displacement chromatography
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014142882A1 (en) *	2013-03-14	2014-09-18	Abbvie Inc.	Protein purification using displacement chromatography
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
KR20150129033A (ko)	2013-03-14	2015-11-18	애브비 인코포레이티드	저 산성 종 조성물 및 이의 제조 및 사용 방법
EP2855533A4 (en)	2013-03-15	2015-11-25	Momenta Pharmaceuticals Inc	METHODS RELATING TO CTLA4-FC FUSION PROTEINS
BR112015023797A2 (pt)	2013-03-15	2017-10-24	Abbvie Inc	proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US10464996B2 (en)	2013-05-13	2019-11-05	Momenta Pharmaceuticals, Inc.	Methods for the treatment of neurodegeneration
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US20160257754A1 (en)	2013-10-16	2016-09-08	Momenta Pharmaceuticals Inc.	Sialylated glycoproteins
JP6526025B2 (ja)	2013-10-16	2019-06-05	オンコバイオロジクス，インコーポレイティド	抗体安定性を増強する緩衝液製剤
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
US20170226552A1 (en)	2014-07-03	2017-08-10	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en)	2014-07-09	2016-01-14	Abbvie Inc.	Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
CN105727285B (zh) *	2014-12-10	2018-06-19	信达生物制药(苏州)有限公司	一种单克隆抗体在治疗神经退行性疾病中的应用
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
KR101776879B1 (ko)	2015-01-19	2017-09-08	주식회사 녹십자	항-egfr 항체를 포함하는 약학 제제
WO2016118707A1 (en)	2015-01-21	2016-07-28	Oncobiologics, Inc.	Modulation of charge variants in a monoclonal antibody composition
AR103726A1 (es) *	2015-02-27	2017-05-31	Merck Sharp & Dohme	Cristales de anticuerpos monoclonales anti-pd-1 humanos
AU2016226418B2 (en)	2015-03-02	2022-05-26	Synthetic Genomics, Inc.	Regulatory elements from labyrinthulomycetes microorganisms
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2018009341A (es)	2016-02-03	2019-05-15	Oncobiologics Inc	Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
AU2017235543B2 (en)	2016-03-16	2020-05-14	Conagen, Inc.	Production of proteins in labyrinthulomycetes
EP3528787A4 (en)	2016-10-21	2020-05-06	Amgen Inc.	PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
US10633454B2 (en)	2016-11-01	2020-04-28	Conagen Inc.	Expression of modified glycoproteins and glycopeptides
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
BR112019022873A8 (pt)	2017-05-02	2023-04-11	Merck Sharp & Dohme	Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102208378B1 (ko) *	2017-08-17	2021-01-28	주식회사 녹십자	항-egfr 항체를 포함하는 약학 제제
WO2019147824A1 (en)	2018-01-26	2019-08-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20230033021A1 (en)	2018-06-20	2023-02-02	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246313A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3810268A1 (en)	2018-06-20	2021-04-28	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US12171764B2 (en)	2018-06-20	2024-12-24	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
MX2021005394A (es)	2018-11-07	2021-07-06	Merck Sharp & Dohme Llc	Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3631229A1 (de)	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US6498237B2 (en)	1989-08-07	2002-12-24	Peptech Limited	Tumor necrosis factor antibodies
US5618710A (en)	1990-08-03	1997-04-08	Vertex Pharmaceuticals, Inc.	Crosslinked enzyme crystals
US20040120952A1 (en)	2000-08-07	2004-06-24	Centocor, Inc	Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en)	1991-03-18	2006-11-02	Knight David M	Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US20070298040A1 (en)	1991-03-18	2007-12-27	Centocor, Inc.	Methods of treating seronegative arthropathy with anti-TNF antibodies
US5656272A (en)	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
CN103275221B (zh) *	1996-02-09	2016-08-17	艾伯维生物技术有限公司	结合人TNFα的人抗体
US20060018907A1 (en)	2000-08-07	2006-01-26	Centocor, Inc.	Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050249735A1 (en)	2000-08-07	2005-11-10	Centocor, Inc.	Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
EP2325205A3 (en) *	2000-12-28	2011-10-12	Altus Pharmaceuticals Inc.	Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030012786A1 (en)	2001-05-25	2003-01-16	Teoh Leah S.	Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
CA2868614A1 (en)	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US6909382B2 (en) *	2001-07-12	2005-06-21	Anders Trell Trust	Polyphonic/chordic annotation method
US20030161828A1 (en)	2002-02-19	2003-08-28	Abbott Gmbh & Co. Kg	Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20040009172A1 (en)	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
DE10228103A1 (de)	2002-06-24	2004-01-15	Bayer Cropscience Ag	Fungizide Wirkstoffkombinationen
NZ563452A (en) *	2002-07-19	2010-04-30	Abbott Biotech Ltd	Treatment of TNFalpha related disorders
US20090280065A1 (en)	2006-04-10	2009-11-12	Willian Mary K	Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en)	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
EP1685282A2 (en)	2003-04-17	2006-08-02	Fluidigm Corporation	Crystal growth devices and systems, and methods for using same
US7563748B2 (en)	2003-06-23	2009-07-21	Cognis Ip Management Gmbh	Alcohol alkoxylate carriers for pesticide active ingredients
DE10355904A1 (de) *	2003-11-29	2005-06-30	Merck Patent Gmbh	Feste Formen von anti-EGFR-Antikörpern
TWI556829B (zh)	2004-04-09	2016-11-11	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
WO2006000020A1 (en)	2004-06-29	2006-01-05	European Nickel Plc	Improved leaching of base metals
RU2442571C2 (ru)	2004-07-23	2012-02-20	Дженентек, Инк.	Кристаллизация антител или их фрагментов
WO2006041970A2 (en)	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
JP2008523842A (ja)	2004-12-21	2008-07-10	セントカー・インコーポレーテツド	抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
EP2500037A3 (en)	2005-05-16	2012-10-24	Abbott Biotechnology Ltd	Use of TNF alpha inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
EP1948235B1 (en)	2005-11-01	2013-08-28	AbbVie Biotechnology Ltd	Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
EP2738178A1 (en)	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Antibody purification
US9605064B2 (en)	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
WO2007120656A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (en)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Uses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en)	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en)	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of ankylosing spondylitis
US20080131374A1 (en)	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en)	2006-06-08	2008-12-18	Hoffman Rebecca S	Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en)	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
TW200801513A (en)	2006-06-29	2008-01-01	Fermiscan Australia Pty Ltd	Improved process
WO2008005315A2 (en)	2006-06-30	2008-01-10	Abbott Biotechnology Ltd.	Automatic injection device
RU2518289C2 (ru)	2006-09-13	2014-06-10	Эббви Инк,	Способ получения антитела или его фрагмента с подпиткой (варианты)
BRPI0717335A2 (pt)	2006-10-27	2013-12-10	Abbott Biotech Ltd	Anticorpos anti-htnfalfa cristalinos
MX2009010361A (es) *	2007-03-29	2009-10-16	Abbott Lab	Anticuerpos il-12 anti-humanos cristalinos.
US8092998B2 (en)	2007-05-31	2012-01-10	Abbott Laboratories	Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
WO2008150490A2 (en)	2007-06-01	2008-12-11	Abbott Biotechnology Ltd.	Uses and compositions for treatment of psoriasis and crohn's disease
EP2171451A4 (en)	2007-06-11	2011-12-07	Abbott Biotech Ltd	METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CA2693771A1 (en)	2007-07-13	2009-01-22	Abbott Biotechnology Ltd.	Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
SG183709A1 (en) *	2007-08-08	2012-09-27	Abbott Lab	Compositions and methods for crystallizing antibodies
CA2696210A1 (en)	2007-08-28	2009-03-12	Abbott Biotechnology Ltd.	Compositions and methods comprising binding proteins for adalimumab
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
MX2010007393A (es)	2008-01-03	2010-11-09	Abbott Biotech Ltd	Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
JP6078217B2 (ja)	2008-01-15	2017-02-08	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	粉末化されたタンパク質組成物及びその作製方法
EP2784089A1 (en)	2008-01-15	2014-10-01	AbbVie Inc.	Improved mammalian expression vectors and uses thereof
CN102065892A (zh)	2008-01-30	2011-05-18	雅培制药有限公司	用于使抗体片段结晶的组合物和方法
WO2009118662A2 (en)	2008-03-24	2009-10-01	Abbott Biotechnology Ltd.	Methods and compositions for treating bone loss
US8636704B2 (en)	2009-04-29	2014-01-28	Abbvie Biotechnology Ltd	Automatic injection device
SG175188A1 (en)	2009-05-04	2011-11-28	Abbott Biotech Ltd	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011097301A2 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
PL2575884T3 (pl)	2010-06-03	2018-12-31	Abbvie Biotechnology Ltd	Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)

2007
- 2007-10-25 BR BRPI0717335-0A2A patent/BRPI0717335A2/pt not_active IP Right Cessation
- 2007-10-25 CN CN200780040145A patent/CN101616932A/zh active Pending
- 2007-10-25 ES ES07852953.4T patent/ES2442258T3/es active Active
- 2007-10-25 EP EP07852953.4A patent/EP2089428B1/en active Active
- 2007-10-25 EP EP13186181.7A patent/EP2684895A1/en not_active Withdrawn
- 2007-10-25 NZ NZ597676A patent/NZ597676A/xx not_active IP Right Cessation
- 2007-10-25 KR KR1020097010790A patent/KR20090101893A/ko not_active Ceased
- 2007-10-25 NZ NZ613356A patent/NZ613356A/en not_active IP Right Cessation
- 2007-10-25 CA CA002667655A patent/CA2667655A1/en not_active Abandoned
- 2007-10-25 SG SG2011078698A patent/SG176427A1/en unknown
- 2007-10-25 WO PCT/US2007/022622 patent/WO2008057240A2/en active Search and Examination
- 2007-10-25 CN CN201310234752.XA patent/CN104072612A/zh active Pending
- 2007-10-25 JP JP2009534651A patent/JP2010507670A/ja not_active Withdrawn
- 2007-10-25 MX MX2009004351A patent/MX2009004351A/es active IP Right Grant
- 2007-10-25 KR KR1020147033811A patent/KR20150002896A/ko not_active Withdrawn
- 2007-10-25 NZ NZ576133A patent/NZ576133A/xx not_active IP Right Cessation
- 2007-10-25 AU AU2007318120A patent/AU2007318120B2/en not_active Ceased
- 2007-10-25 RU RU2009119988/10A patent/RU2486296C2/ru not_active IP Right Cessation
- 2007-10-25 US US11/977,677 patent/US8034906B2/en not_active Expired - Fee Related
- 2007-10-26 PE PE2007001461A patent/PE20081258A1/es not_active Application Discontinuation
- 2007-10-26 PE PE2012000080A patent/PE20120663A1/es not_active Application Discontinuation
- 2007-10-26 TW TW096140427A patent/TWI417302B/zh not_active IP Right Cessation
- 2007-10-26 CL CL200703094A patent/CL2007003094A1/es unknown
- 2007-10-26 AR ARP070104770A patent/AR063429A1/es unknown
- 2007-10-26 TW TW102136081A patent/TW201429987A/zh unknown
- 2007-10-29 UY UY30662A patent/UY30662A1/es not_active Application Discontinuation
2009
- 2009-04-19 IL IL198223A patent/IL198223A/en not_active IP Right Cessation
2011
- 2011-09-02 US US13/225,281 patent/US8436149B2/en active Active
2013
- 2013-01-24 RU RU2013103322/10A patent/RU2013103322A/ru unknown
- 2013-02-22 US US13/774,706 patent/US8772458B2/en active Active
- 2013-04-01 JP JP2013076296A patent/JP2013166758A/ja active Pending
- 2013-08-23 ZA ZA2013/06383A patent/ZA201306383B/en unknown
2014
- 2014-06-19 US US14/309,208 patent/US20150183863A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2667655A1 (en)	2008-05-15
JP2013166758A (ja)	2013-08-29
AU2007318120B2 (en)	2013-07-25
WO2008057240A9 (en)	2008-08-28
EP2089428A2 (en)	2009-08-19
TW201429987A (zh)	2014-08-01
WO2008057240A2 (en)	2008-05-15
US20100034823A1 (en)	2010-02-11
US20120251550A1 (en)	2012-10-04
ES2442258T3 (es)	2014-02-10
HK1129400A1 (en)	2009-11-27
PE20081258A1 (es)	2008-09-04
PE20120663A1 (es)	2012-06-01
EP2089428B1 (en)	2013-11-20
RU2009119988A (ru)	2010-12-10
NZ613356A (en)	2015-02-27
UY30662A1 (es)	2008-05-31
KR20090101893A (ko)	2009-09-29
US8436149B2 (en)	2013-05-07
JP2010507670A (ja)	2010-03-11
CN104072612A (zh)	2014-10-01
ZA201306383B (en)	2014-04-30
NZ597676A (en)	2013-07-26
EP2089428A4 (en)	2010-11-03
RU2486296C2 (ru)	2013-06-27
US8034906B2 (en)	2011-10-11
TW200835699A (en)	2008-09-01
US20130309309A1 (en)	2013-11-21
CL2007003094A1 (es)	2008-05-16
IL198223A0 (en)	2011-08-01
NZ576133A (en)	2012-10-26
IL198223A (en)	2014-05-28
EP2684895A1 (en)	2014-01-15
MX2009004351A (es)	2009-05-12
US20150183863A1 (en)	2015-07-02
WO2008057240A3 (en)	2008-11-06
TWI417302B (zh)	2013-12-01
CN101616932A (zh)	2009-12-30
KR20150002896A (ko)	2015-01-07
SG176427A1 (en)	2011-12-29
AR063429A1 (es)	2009-01-28
RU2013103322A (ru)	2014-07-27
US8772458B2 (en)	2014-07-08
AU2007318120A1 (en)	2008-05-15

Publication	Publication Date	Title
BRPI0717335A2 (pt)	2013-12-10	Anticorpos anti-htnfalfa cristalinos
MX2010001488A (es)	2010-03-01	Composiciones y metodos para cristalizar anticuerpos.
MX2009010361A (es)	2009-10-16	Anticuerpos il-12 anti-humanos cristalinos.
EA201490457A1 (ru)	2014-07-30	Способ получения тернесит-белит-кальций-сульфоалюминатного клинкера
EP2202335A4 (en)	2011-09-14	QUARTZ GLASS CUP FOR DRAWING A SILICON MONOCRYSTAL AND METHOD FOR MANUFACTURING THE CUTTER
BR112013011593A2 (pt)	2016-08-09	cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
DK2084287T3 (da)	2012-07-23	Fremgangsmåde til biologisk fremstilling af n-butanol med højt udbytte
CL2008001887A1 (es)	2008-10-03	Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
EA201200117A1 (ru)	2012-08-30	Способ получения водной суспензии органического пестицидного соединения
ATE554105T1 (de)	2012-05-15	Veränderte antikörper
EA201391389A1 (ru)	2014-03-31	Кристаллы антител против склеростина и составы на их основе
EA200970247A1 (ru)	2009-08-28	Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
CL2011002360A1 (es)	2012-07-20	Anticuerpo anti-alfa5beta1; molecula de acido nucleico que codifica el anticuerpo;celula huesped; metodo para produccionde anticuerpos anti-alfa5beta1; inmunoconjugado que comprende el anticuerpo; composicion farmaceutica.
BRPI0519624A2 (pt)	2009-02-25	processos para produÇço de ansamitocinas
PL394857A1 (pl)	2011-09-26	Sposób amonotermalnego wytwarzania kryształów ciągnionych azotku galu na dużą skalę
CY1112829T1 (el)	2016-02-10	Νεα μεθοδος συνθεσης για την αγομελατινη
BRPI0507034A (pt)	2007-06-05	compostos orgánicos
MA30079B1 (fr)	2008-12-01	Procede de synthese de ferri-succinylcaseine
FR2940266B1 (fr)	2010-12-31	Solide cristallise im-20 et son procede de preparation
NO20075094L (no)	2008-01-09	Fremstilling av ammoniumdinitroamid(ADN)krystaller, krystallene og de energirike sammensetninger som inneholder disse krystallene
CY1114562T1 (el)	2016-10-05	Υψηλης καθαροτητας μεγαλης κλιμακας παρασκευη στανσοπορφινης
EA200870038A1 (ru)	2008-10-30	Способ получения аминов
BR112014027994A2 (pt)	2017-06-27	métodos de cristalização para purificação de anticorpos monoclonais
ATE528259T1 (de)	2011-10-15	Kristallisierter im-18-festkörper und herstellungsverfahren dafür
EA201000464A1 (ru)	2010-08-30	Способ получения очищенного синтез-газа из синтез-газа, содержащего следовые количества примеси сернистых соединений, с помощью металлорганической структуры

Legal Events

Date	Code	Title	Description
2016-01-12	B25D	Requested change of name of applicant approved	Owner name: ABBVIE BIOTECHNOLOGY LTD. (BM)
2016-06-14	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.